Company Overview and News

0
Premier African raises £750,000 to support work on the RHA tungsten project

2018-08-14 proactiveinvestors.com.au
The money raised will be allocated to the restructuring and ongoing holding costs of the RHA tungsten mine and plans to bring it back into production.
WLFE WLF WFMRF

0
Wolf executes debt restructuring deal

2018-08-14 proactiveinvestors.com.au
Wolf Minerals LTD (LON:WLFE) has executed its previously announced debt restructuring deal which involves the deferred payment of principal, interest and other amounts due at the end of July 2018.
WLFE WLF WFMRF

0
Wolf Minerals extends bridging facility

2018-07-30 proactiveinvestors.com.au
Wolf Minerals LTD (ASX:WLF)(LON:WLFE) has extended its existing bridge facility from £65mln to £69mln, with £2m of the new money available immediately.
WLF WLFE WFMRF

0
Wolf Minerals recovers operating strength following March freeze as it seeks new funds

2018-07-18 proactiveinvestors.com.au
Wolf Minerals Limited (LON:WLFE ASX:WLF) has reported improvements in its operating strength at its Drakelands mine in Devon following the March cold snap as it sought new funds from investors.
WLF WLFE WFMRF

1
Wolf Minerals settles dispute with GR Engineering over Hemerdon contract

2018-04-20 proactiveinvestors.com.au
Wolf Minerals Ltd (LON:WLFE) said it has settled a dispute with GR Engineering over a contract for the Hemerdon tungsten and tin project.
WLFE WLF WFMRF

1
Turnaround plan at Wolf Minerals proceeding apace

2018-04-18 proactiveinvestors.com.au
Wolf Minerals Ltd (LON:WLFE) operates one of the world’s major tungsten mines at Drakelands in the southwest of England.
WLFE WLF WFMRF

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...